

Table 2. Outcomes of drug allergy evaluation

Drug class (n=331) No. (%)	Negative drug evaluation (false drug allergy label) (n=248) No. (%)	Positive drug evaluation (true drug allergy label) (n=83) No. (%)	Number of positive evaluations ^a			
			Skin testing		In-clinic graded challenge (n=331) No. (%) ^b	Home prolonged evaluation (n=134) No. (%) ^b
			Skin prick test (n=237) No. (%) ^b	Intra- dermal test (n=237) No. (%) ^b		
Beta-lactam antibiotics 170 (51)	114 (46)	56 (68)	1/170 (0.4)	9/170 (4)	25/170 (8)	21/102 (16) ^c
Peri-operative drugs 53 (16)	48 (19)	5 (6)	0/53 (0)	3/53 (1)	2/53 (0.6)	0
NSAIDs 38 (12)	25 (10)	13 (16)	0	0	12/38 (4)	1/3 (0.7) ^d
Non-beta-lactam antibiotics 27 (8)	24 (10)	3 (4)	0/3 (0)	0/3 (0)	2/27 (0.6)	1/18 (0.7) ^e
Others 43 (13)	37 (15)	6 (7)	0/11 (0)	3/11 (1)	3/43 (0.9)	0/11 (0)
Total	248 (100)	83 (100)	1 (0.4)	15 (6)	44 (13)	23 (17)

NSAIDs: non-steroidal anti-inflammatory drugs

^a Number of positive evaluations out of total number of evaluations done per drug class.

^b Percentage calculated using denominator of total number of evaluations performed across all drug classes (column percentage).

^c Among the 21 reactions that occurred in beta-lactam antibiotics prolonged evaluations, 2 occurred on day 1, 5 on day 2, 5 on day 3, 1 on day 4, 2 on day 5, and 6 on day 6.

^d Delayed reaction occurred on day 2.

^e Delayed reaction occurred on day 3.